QIAstat-Dx uses real-time PCR technology to multiply genetic targets within the same reaction and deliver test results in around one hour.

The company has three clinical CAR-T programmes backed by its precision-targeting cellular system Imod platform technology.

Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...

Biotech competition between the U.S. and China "will not only have implications for our national and economic security, but also for the future of healthcare and the security of American medical data, ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

The cost of a carton is soaring nationwide, breaking new records as the bird flu outbreak grows. Zoom out: A dozen large eggs ...

Following the FDA’s release of a guidance requesting more diversity in pulse oximeter testing, the number of clearance ...

Additionally, rapid, substantial and sustained statistically significant reductions in 17-OHP, a confirmatory secondary biomarker of disease control, were achieved across doses. Treatment with ...

Documentary series Culturally Plant-Based explores vegan and vegetarian culinary traditions and will focus on Thailand for its first season ...